<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716647</url>
  </required_header>
  <id_info>
    <org_study_id>AU/2187</org_study_id>
    <nct_id>NCT04716647</nct_id>
  </id_info>
  <brief_title>Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research</brief_title>
  <official_title>A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarogyam UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarogyam UK</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Innovative strategies are required to manage COVID-19 in the communities. Back to Roots&#xD;
      community based project was a collaborative, pilot intervention program in British Asian&#xD;
      community to assess the efficacy and safety of Ayurveda intervention in relieving symptoms of&#xD;
      mild-to-moderate COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Community Based Participatory Research</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical recovery</measure>
    <time_frame>Up to 14-days</time_frame>
    <description>To evaluate the therapeutic efficacy, mean days for clinical recovery were recorded from AiM Covid Application</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patient with negative conversion in nasopharyngeal swab</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>To evaluate the therapeutic efficacy, promotion of patients were recorded through AiM Covid application</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>Up to 14-days</time_frame>
    <description>Clinical Outcome was recorded on 7-pont ordinal scale of COVID-19</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ayurveda Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ayurveda</intervention_name>
    <description>Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.</description>
    <arm_group_label>Ayurveda Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With SARS-CoV-2 infection confirmed through reverse transcription followed by&#xD;
             polymerase chain reaction (RT- PCR),&#xD;
&#xD;
          -  With mild or moderate manifestations of COVID-19&#xD;
&#xD;
          -  Willing to participate, and consent by signing the informed consent and&#xD;
&#xD;
          -  not involved in another clinical trial during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from severe COVID-19 Disease as per World Health Organisation&#xD;
             criteria (REF)&#xD;
&#xD;
          -  Any of the known COVID-19 complications and emergency procedures which may require&#xD;
             shift/admission in hospital for oxygen support or intensive care unit&#xD;
&#xD;
          -  Patients with ongoing immunosuppressive therapy for any reasons&#xD;
&#xD;
          -  Active cancer diagnosis, on palliative treatment or requiring current therapy with&#xD;
             antimetabolic agents, immunotherapy or radiotherapy.&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Ayurveda practitioner decision that involvement in the study is not in the patient's&#xD;
             best interest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Sharma</last_name>
    <role>Study Director</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dipa Modi</last_name>
    <role>Study Chair</role>
    <affiliation>East Park Medical Centre, NHS trust, Leicester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vishwesh Kulkarni</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Warwick</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhimanyu Kumar</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarogyam UK</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ayurveda Intervention, Community Based Participatory Research</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

